Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 20011-20020 Newer>

The Motley Fool January 23, 2007 Rich Smith	Foolish Forecast: DeVry Graduates The for-profit educator is set to report fiscal second-quarter 2007 earnings results. Investors, do yo want to know what Wall Street expects to see? Do you want to know what really matters?
The Motley Fool January 23, 2007 Seth Jayson	'Tis the Season Chinese medical device maker Mindray Medical $309 million offering looks to be all insider selling. Investors, take note.
The Motley Fool January 23, 2007 Nathan Parmelee	Jovial Johnson & Johnson: Fool by Numbers The health-care conglomerate released full-year 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet and Cash Flow Highlights...
The Motley Fool January 23, 2007 Anders Bylund	Foolish Forecast: Slumbering Seagate The leading hard drive maker is set to report earnings for the second quarter of fiscal year 2007. Investors, here's what to expect.
The Motley Fool January 23, 2007 Will Frankenhoff	Turkcell: Investors' Best Call? Put investing in Turkey's dominant cellular operator on speed dial.
The Motley Fool January 23, 2007 Rick Aristotle Munarriz	Gap Presses Pressler's Luck The specialty retailer may finally have an exit strategy. Investors, take note.
The Motley Fool January 23, 2007 Rick Aristotle Munarriz	Netflix Bucks the Trend The video-rental site makes its cheapest plan even cheaper. Should investors panic?
The Motley Fool January 23, 2007 Steven Mallas	Take-Two's Option Game Like many other companies, Take-Two Interactive has problems with options. Should investors avoid it?
The Motley Fool January 23, 2007 Brian Lawler	No Generic Profit for Reddy Investors looking to hedge a pharmaceutical position in case of adverse congressional legislation (or those looking for an international company in booming India) might do well to look at Dr. Reddy's.
The Motley Fool January 23, 2007 Ryan Fuhrmann	Back to the Future at Pfizer Pfizer just provided guidance for the next couple of years. The news shows that the company is willing to shake things up, but investors should remain skeptical until tangible benefits occur.
<Older 20011-20020 Newer> Return to current articles.